Adial Pharmaceuticals, Inc. Operating Lease, Expense
Adial Pharmaceuticals, Inc. (ADIL) reported Operating Lease, Expense of $18.21 thousand for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-12.
Discontinued › Expense Statement › Operating Expenses
us-gaap:OperatingLeaseExpense · last filed 2023-05-12
- Adial Pharmaceuticals, Inc. operating lease, expense for the quarter ending 2023-03-31 was $18.21K, a 6.03% decline year-over-year.
- Adial Pharmaceuticals, Inc. operating lease, expense for the quarter ending 2022-12-31 was $12.34K, a 35.15% decline year-over-year.
- Adial Pharmaceuticals, Inc. operating lease, expense for the quarter ending 2022-09-30 was $19.63K, a 11.68% decline year-over-year.
- Adial Pharmaceuticals, Inc. operating lease, expense for the quarter ending 2022-06-30 was $21.48K, a 13.40% increase year-over-year.
- Adial Pharmaceuticals, Inc. operating lease, expense for fiscal 2022 was $72.83K, a 3.05% decline from fiscal 2021.
- Adial Pharmaceuticals, Inc. operating lease, expense for fiscal 2021 was $75.12K.
| Period end | Operating Lease, Expense 3 month | Operating Lease, Expense 6 month | Operating Lease, Expense 9 month | Operating Lease, Expense 12 month |
|---|---|---|---|---|
| 2023-03-31 | $18.21K 10-Q · filed 2023-05-12 | $30.55K derived: sum of 2 quarters · filed 2023-05-12 | $50.18K derived: sum of 3 quarters · filed 2023-05-12 | $71.66K derived: sum of 4 quarters · filed 2023-05-12 |
| 2022-12-31 | $12.34K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $31.97K derived: sum of 2 quarters · filed 2023-03-30 | $53.45K derived: sum of 3 quarters · filed 2023-03-30 | $72.83K 10-K · filed 2023-03-30 |
| 2022-09-30 | $19.63K 10-Q · filed 2022-11-14 | $41.11K derived: sum of 2 quarters · filed 2022-11-14 | $60.49K 10-Q · filed 2022-11-14 | $79.52K derived: sum of 4 quarters · filed 2023-05-12 |
| 2022-06-30 | $21.48K 10-Q · filed 2022-08-15 | $40.86K 10-Q · filed 2022-08-15 | $59.88K derived: sum of 3 quarters · filed 2023-05-12 | $82.11K derived: sum of 4 quarters · filed 2023-05-12 |
| 2022-03-31 | $19.38K 10-Q · filed 2023-05-12 | $38.40K derived: sum of 2 quarters · filed 2023-05-12 | $60.63K derived: sum of 3 quarters · filed 2023-05-12 | $79.58K derived: sum of 4 quarters · filed 2023-05-12 |
| 2021-12-31 | $19.03K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-30 | $41.26K derived: sum of 2 quarters · filed 2023-03-30 | $60.20K derived: sum of 3 quarters · filed 2023-03-30 | $75.12K 10-K · filed 2023-03-30 |
| 2021-09-30 | $22.23K 10-Q · filed 2022-11-14 | $41.17K derived: sum of 2 quarters · filed 2022-11-14 | $56.09K 10-Q · filed 2022-11-14 | |
| 2021-06-30 | $18.94K 10-Q · filed 2022-08-15 | $33.86K 10-Q · filed 2022-08-15 | ||
| 2021-03-31 | $18.21K 10-Q · filed 2022-05-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |